The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors? US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Pharmaceutical Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Inception Date: 20/12/2011
Primary Benchmark: MVIS US Listed Pharmaceutical 25 NR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.41%
Management Expense Ratio: 0.35 %
|TEVA||Teva Pharmaceutical Industries Limited American Depositary Shares||5.64 %|
|AZN||Astrazeneca PLC||5.11 %|
|VRX||Valeant Pharmaceuticals International Inc.||5.03 %|
|MRK||Merck & Company Inc. (new)||4.90 %|
|NVO||Novo Nordisk A/S||4.87 %|
|MYL||Mylan N.V.||4.86 %|
|GSK||GlaxoSmithKline PLC||4.85 %|
|ABBV||AbbVie Inc.||4.83 %|
|PFE||Pfizer Inc.||4.81 %|
|NVS||Novartis AG||4.77 %|
|IBB||iShares Nasdaq Biotechnology I..||0.47 %||
|BBH||VanEck Vectors Biotech ETF||0.35 %||
|PSCH||PowerShares S&P SmallCap Healt..||0.29 %||
|PTH||PowerShares DWA Healthcare Mom..||0.60 %||
|GNRX||Market Vectors Generic Drugs E..||0.55 %||
|SLIM||The Obesity ETF||0.50 %||
|BFIT||Global X Health & Wellness The..||0.68 %||
|CNCR||Loncar Cancer Immunotherapy ET..||0.79 %||
|LNGR||Global X Longevity Thematic ET..||0.68 %||
|Market Performance vs.
|Market Performance vs. Exchange (NASDAQ Global Market)|
|Value||Sector Median||Percentile Rank||Grade||Market Median||Percentile Rank||Grade|
|Trailing 12 Months|
|Trailing 5 Years|
|Average Annual (5 Year Horizon)|
|Risk Return Profile|
|Volatility (Standard Deviation)||18.18%||40%||F||70%||C-|
|Risk Adjusted Return||45.28%||30%||F||52%||F|
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.